Hospital
Wakemed
Wakemed was paid $4.12M by Medicaid between Jan 2018 and Dec 2024, across 35 billing codes. Its largest line is 99284, emergency room visit (serious) — 69% of everything it billed.
33Billing provider infoWAKEMED
CARY, NC 27518
CARY, NC 27518
33aNPI1114993086assigned 02/28/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$4.12M
24GClaims36,289
24DCodes billed35
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in North Carolina
Rank by total paid#65 of 92
Median peer was paid$11.47M
This provider vs. median0.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 4,742 | $402K | |
| 2019 | 3,725 | $368K | |
| 2020 | 2,359 | $218K | |
| 2021 | 5,209 | $619K | |
| 2022 | 6,753 | $958K | |
| 2023 | 5,974 | $747K | |
| 2024incomplete | 7,527 | $806K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 69% | 9,922 | 9,312 | $2.85M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 22% | 6,580 | 6,242 | $889K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.9% | 9,039 | 8,333 | $80K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.1% | 242 | 230 | $45K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,295 | 1,194 | $41K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 462 | 432 | $36K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | <1% | 102 | 90 | $34K |
| 80053 | Comprehensive metabolic panel | <1% | 2,910 | 2,668 | $31K |
| 0240U | <1% | 152 | 141 | $24K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 608 | 558 | $19K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 242 | 211 | $11K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 242 | 227 | $8K |
23 more codes
| 83690 | <1% | 882 | $7K | |
| 84703 | <1% | 747 | $7K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 97 | $6K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 12 | $4K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 37 | $4K |
| 81001 | <1% | 1,018 | $4K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 65 | $3K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 530 | $2K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 214 | $2K |
| 87631 | <1% | 21 | $2K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 84 | $2K |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 14 | $2K |
| 81003 | <1% | 417 | $955.52 | |
| 84484 | <1% | 46 | $674.56 | |
| 87430 | <1% | 44 | $571.20 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 14 | $550.69 |
| 59025 | Fetal non-stress test | <1% | 13 | $529.70 |
| 71045 | Radiologic examination, chest; single view | <1% | 13 | $521.44 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 41 | $341.70 |
| 87081 | <1% | 40 | $258.48 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 15 | $118.05 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 77 | $53.75 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 52 | $29.78 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSESSOMS, STEPHANIE (EXECUTIVE VP, FINANCE & CFO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.